

To: (10)(2e) (10)(2e)@rivm.nl]
Bcc: (10)(2e) (10)(2e)@rivm.nl]
From: VraagAanbodTriage
Sent: Tue 6/2/2020 9:12:08 AM
Subject: FW: Melding nr. M2005 10034 onderwerp: [Spam] C19passport
Received: Tue 6/2/2020 9:12:09 AM
[C19passport Prelaunch information ENG 20200526.pdf](#)
[C19Passport Product description PSD01.pdf](#)

Beste (10)(2e)

Wil jij onderstaand aanbod opnemen in de beschikbare systemen?

Groeten (10)(2e)
 VraagAanbodTriage RIVM

Verzoek:

E-mail adres: (10)(2e)@ (10)(2e) .se
 Date sent: May 28, 2020 8:37 AM
 To: "info@rivm.nl" <info@rivm.nl>
 CC: (10)(2e) <(10)(2e)@ (10)(2e) .se>
 Subject: [Spam] C19passport

Dear Madam or Sir,

Upcoming months pharma solution company Lakameda launch the infrastructure for voluntary registration of test result and in future vaccination for COVID 19.

C19passport is an international database with a complete system supporting the integrity and safety of individuals.
 C19passport is self-financed by the users- the individuals who buy the registration.

Primary intention of use are as a proof of a test (or vaccination) performed by an authorised institution.

Secondary possible benefits for the individual- e.g. different countries use the option of dynamic recommendations- in relation to test brand and test results.

Massive testing is ongoing- already performed test can be registered provided the institution gets authorised to the system.

We offer you to validate the system and get more information- with the intention of recognition C19passport and C19safecard as a proof of test in travelling.

Nations can evaluate the option to provide customised recommendations for inhabitants or travellers.

Launch will be in order of national interest, starting with Lithuania and Sweden in July.

Please see PDF attached and for more information please visit our website <https://www.lakameda.lt/c19-passport/>
 For contact please reply to me or to info@lakameda.lt.

(10)(2e)

lakameda+

+ (10)(2e)
 (10)(2e)@tollerud.se
 UAB Lakameda
 Aušros g. 42A, Kaunas
 LT-44156